1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. GLAND PHARMA LTD.
Gland Pharma Ltd.
NSE: GLAND | BSE: 543245

Gland Pharma Live Share Price Today, Share Analysis and Chart

Strong Performer, Getting Expensive
BasketIn 1 Starfolio Basket
aboutGland Pharma Limited (Gland Pharma) is a Hyderabad-based generic injectables manufacturer with a significant global footprint in regulated markets, including the USA, Europe, Canada, and Australia. The company operates primarily through a B2B model, ... Read More
US FDA InspectionsANDA Approvals
Ask AI about Gland Pharma
3095.9021.40(0.70%)

Near 52W High of ₹3171.00

395.6K
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Gland Pharma is on 06 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
75.0 / 100
Strong Performer, Getting ExpensiveThese stocks are strong in quality and technicals but have medium valuation. At somewhat expensive valuations, investors should be cautious before buyingView SimilarEmbed DVM
Analyst Price Target
-

30

S

7

W

10

O

2

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

17Positive6Negative

Pass in checklist73.9%

045
55
100

PE Valuation Check

Right Now
Overvalued
-20.7%
1 Year Forward
Overvalued
-7.4%
INSIGHTGland Pharma is overvalued at both current PE and future earnings estimates.

Gland Pharma Stock Price Analysis

Day Price Range

0.7% 1 Day return
3095.9 (LTP)
3,0513,114.2
LowHigh

Week Price Range

9.5% 1 Week return
3095.9 (LTP)
2,788.43,114.2
LowHigh

Month Price Range

6.8% 1 Month return
3095.9 (LTP)
2,769.83,171
LowHigh

52 Week Price Range

60.5% 1 Year return
3095.9 (LTP)
1,573.63,171
LowHigh
View full Price History/Seasonality

Gland Pharma Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Gland Pharma's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
62.3
AVG. ESTIMATE
79.5
LOW ESTIMATE
73
HIGH ESTIMATE
85.3
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 27.7% in FY27

Consensus Recommendation

14 ANALYST Recommendations
BUY

The consensus recommendation from 14 analysts for Gland Pharma is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Gland Pharma Technical Analysis

Gland Pharma EMA & SMA

Bullish+8
8 bullish, 0 bearish
Bullish8
Bearish0
5 Day3030.1
10 Day3002.6
12 Day2998.7
20 Day2987.2
26 Day2976.2
50 Day2905.1
100 Day2714.6
200 Day2436.7

Gland Pharma Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202667.4%
Week65.4%
Month60.3%

Gland Pharma Active Candlesticks

Short Line Uptrend Advance Block Downtrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Gland Pharma Resistance and Support

3087.03
Pivot
First Resistance3123.1
Second Resistance3150.2
Third Resistance3186.3
First Support3059.9
Second Support3023.8
Third Support2996.7
Day RSI60
Day MACD22.5
Day MFI40.8
Day MACD Signal Line18.7

Gland Pharma Beta

1 Month0.6
1 Year0.6
3 Month0.4
3 Year0.7

Gland Pharma Price Change Analysis

↑6.8%
Over 1 Month
LowHigh
2769.83171
↑23.7%
Over 3 Months
LowHigh
2494.13171
↑76.8%
Over 6 Months
LowHigh
17483171
↑60.5%
Over 1 Year
LowHigh
1573.63171
All Technicals →

Gland Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Fosun Pharma Industrial Pte. LtdPromoter75,496,89445.8 %
Government Pension Fund GlobalFii2,169,9821.3 %
Hdfc Mutual Fund - Hdfc Mid-Cap FundDii9,242,6905.6 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Gland Pharma Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
NORTH ROCK SG VCCBlockSell17 Sep 20262826.60150,000NSE
BOFA SECURITIES EUROPE SABlockPurchase17 Sep 20262826.60150,000NSE
FOSUN PHARMA INDUSTRIAL PTE. LTD.BlockSell04 Sep 20262826.602,793,000BSE
FOSUN PHARMA INDUSTRIAL PTE. LTD.BlockSell04 Sep 20262826.601,357,000BSE
FOSUN PHARMA INDUSTRIAL PTE. LTD.BlockSell04 Sep 20262826.601,039,000BSE
FOSUN PHARMA INDUSTRIAL PTE. LTD.BlockSell04 Sep 20262826.60541,500BSE
FOSUN PHARMA INDUSTRIAL PTE. LTD.BlockSell04 Sep 20262826.60420,000BSE
FOSUN PHARMA INDUSTRIAL PTE. LTD.BlockSell04 Sep 20262826.60400,000BSE
FOSUN PHARMA INDUSTRIAL PTE. LTD.BlockSell04 Sep 20262826.60270,000BSE
FOSUN PHARMA INDUSTRIAL PTE. LTD.BlockSell04 Sep 20262826.60250,000BSE
All deals
All insider trades

Gland Pharma Corporate Actions

Gland Pharma Dividend history and yield

Gland Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Gland Pharma dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
111 Aug 2026
20FINAL11 Aug 2026Equity Share
214 Aug 2025
18FINAL14 Aug 2025Equity Share
316 Aug 2024
20FINAL16 Aug 2024Equity Share

Gland Pharma Board Meetings

Gland Pharma past and upcoming board meetings.

#Ex-Date
PurposeNotes
106 Nov 2026
Quarterly Results-
210 Aug 2026
Quarterly Results-
315 May 2026
Audited Results & Final Dividend-
428 Jan 2026
Quarterly Results-
503 Nov 2025
Quarterly Results-
All Corporate Actions

Gland Pharma Research Reports

Gland Pharma research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
104 Oct 2026ICICI Direct
Target
34302911.5Buy17.81%6.33%pdf
209 Aug 2026Motilal Oswal
Target
30802667.3Buy15.47%16.07%pdf
321 May 2026ICICI Direct
Target
26452334Buy13.32%32.64%pdf
428 Jan 2026ICICI Direct
Target
22751800.1Buy26.38%71.98%pdf
528 Jan 2026Axis Direct
Reco
21701800.1Buy20.55%71.98%pdf
All Reports of Gland

Gland Pharma Corporate Filings

Gland Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
30 Oct 2026
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Change in Management
Appointment of Mr. Ajay Sahni as the Chief Executive Officer of Gland Pharma International Pte. Ltd (Wholly owned subsidiary of Gland Pharma Limited)
PDF
23 Oct 2026
Gland Pharma Ltd - 543245 - Conclusion Of USFDA Unannounced Inspection At Company''s Formulation Facility At Dundigal, Hyderabad
Conclusion of USFDA Unannounced Inspection at Company''s Formulation Facility at Dundigal, Hyderabad
PDF
21 Oct 2026
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q2FY27 Earnings Call Intimation
PDF
21 Oct 2026
Gland Pharma Ltd - 543245 - Board Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026
Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve Unaudited Financial Results for the Quarter and half year ended September 30, 2026
PDF
12 Oct 2026
Gland Pharma Ltd - 543245 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Reg 74(5) of the SEBI (DP) Regulations, 2018
PDF
VIEW ALL

Gland Pharma DocumentsAsk MarketMind AI

Gland Pharma Earnings Call

Gland Pharma earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
17 Aug 2026Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
10 Aug 2026Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
10 Aug 2026Gland Pharma Results Earnings Call for Q1FY27AudioVideo
20 May 2026Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
15 May 2026Gland Pharma Results Earnings Call for Q4FY26 & Full YearAudioVideo
view all

Gland Pharma Annual Reports

Gland Pharma financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Gland Pharma Credit Ratings

Gland Pharma credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
05 Jun 2018india ratingsIndia Ratings Withdraws Gland Pharma’s RatingsLink
16 Apr 2017india ratingsIndia Ratings Affirms Gland Pharma at ‘IND AA- ’; Outlook StableLink
03 Aug 2014india ratingsInd-Ra Upgrades Gland Pharma to`IND A+`;Outlook StableLink
02 Apr 2013india ratingsInd-Ra Rates Gland Pharma's Additional Bank LoansLink
27 Mar 2013india ratingsInd-Ra Upgrades Gland Pharma to 'IND ALink

Gland Pharma Investor Presentations

Gland Pharma investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
10 Aug 2026Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
15 May 2026Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
28 Jan 2026Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
03 Nov 2025Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
05 Aug 2025Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Gland Pharma - Company Profile

Gland Pharma Management Structure

Gland Pharma management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Ravi Shekhar MitraChief Financial Officer959Mar 26
SAMPATH KUMAR PALLERLAMUDICompany Secretary,Compliance Officer,Vice President188.6Mar 26
Mr. Satnam Singh LoombaChief Operating Officer-Mar 26
Mr. K. Raghuram Chandra RaoHead(Quality)-Mar 26
Mr. Wriddhee MaitraVice President(Human Resources)-Mar 26
Mr. Rvr Prabhakara SastryHead(R & D)-Mar 26
Mr. Surinder KoulHead(Domestic Marketing)-Mar 26
Dr. Jitendra GangwalHead(R & D)-Mar 26
Mr. Prasadha Rao LysettiSenior Vice President,Head(Operations)-Mar 26

Gland Pharma Board of Directors

Gland Pharma Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
SRINIVAS SADUChairman / Executive Director / WTD2875.9Mar 26
SAMPATH KUMAR PALLERLAMUDICS / Compliance Officer / Vice President188.6Mar 26
Naina Lal KidwaiIndependent Non Exe. Director107Mar 26
UDO JAHANNES VETTERIndependent Non Exe. Director39Mar 26
ESSAJI GOOLAM VAHANVATIIndependent Non Exe. Director37Mar 26
Jia Ai (Allen) ZhangNon-Exec & Non-Independent Dir-Mar 26
Wei HuangNon-Exec & Non-Independent Dir-Mar 26
Xingli WangAdditional Director-Mar 26
Website: www.glandpharma.com

About the company - Business Profile

Gland Pharma Limited (Gland Pharma) is a Hyderabad-based generic injectables manufacturer with a significant global footprint in regulated markets, including the USA, Europe, Canada, and Australia. The company operates primarily through a B2B model, providing contract development and manufacturing organization (CDMO) services and out-licensing its generic injectable portfolio. Following the strategic acquisition of Cenexi in 2023, Gland Pharma has expanded its manufacturing capabilities into Europe and enhanced its offerings in complex injectables such as oncology, ophthalmics, and biologics.

Key Points

  • Key Facts: Founded in 1978 in Hyderabad, India, Gland Pharma is listed on both the NSE and BSE. It is a subsidiary of Fosun Pharma, which acquired a majority stake in 2017.
  • Operations and Resources: The company operates 11 manufacturing plants across India and Europe, comprising formulation and API facilities. As of March 31, 2025, Gland Pharma maintains an annual finished formulation capacity of approximately 1,200 million units. Its Indian facilities in Dundigal and Pashamylaram recently received Establishment Inspection Reports (EIRs) from the USFDA.
  • Ownership: Fosun Pharma (Singapore) PTE Ltd is the promoter and parent company. The acquisition of the French CDMO, Cenexi, marked Gland's first major overseas manufacturing expansion.
  • Market Significance: Gland Pharma holds a specialized position in the sterile injectables market. It serves global pharmaceutical companies through long-term supply contracts and profit-sharing B2B models.

Business Model and Capabilities

Gland Pharma’s business model is centered on being a high-volume, quality-led manufacturer of complex injectables. It excels in:

  • B2B IP-Led Model: Developing and filing its own Abbreviated New Drug Applications (ANDAs) and out-licensing them to marketing partners.
  • CDMO Services: Providing fill-and-finish services for biologics, vaccines, and biosimilars.
  • Technology Portfolio: Its complex injectables portfolio (totaling 371 ANDAs as of March 2025) includes advanced delivery technologies:
    • Peptides: 4 products with a Total Addressable Market (TAM) of $2,080 million.
    • Nano Suspensions: 1 product with a TAM of $2,890 million.
    • Suspensions, Microspheres, and Emulsions: Addressing multiple therapeutic areas like CNS health, oncology, and immunology.

Financial Performance (FY2024-25)

Gland Pharma reported consolidated revenue from operations of ₹56,165 million for FY25.

Revenue Breakdown by Customer Location (FY2024-25):

Region Revenue (₹ Mn) % of Total Revenue YoY Change
USA 27,403 49% 2%
Europe 10,225 18% (3)%
India 4,765 8% (19)%
Canada 1,574 3% 77%
Australia 743 1% 19%
Rest of World 11,378 21% (4)%
Total 56,165 100% (1)%

Workforce and Strategic Initiatives

  • Employee Count: The company has a growing workforce of over 4,300 employees as of March 31, 2025.
  • Strategic Initiatives:
    • Cenexi Integration: A multi-year program is underway to modernize Cenexi’s infrastructure and introduce new lines for pre-filled syringes (PFS), vials, and cartridges.
    • Operational Efficiency: Focus on automation and site-specific upgrades (e.g., visual inspection machines) to improve margins.
    • Product Pipeline: Gland Pharma has 1,748 product registrations globally. As of March 2025, it had 318 owned ANDAs, of which 167 are approved and 151 are pending.
  • Future Outlook: The company aims to scale its CDMO capabilities in biologics and high-potency formulations while cross-leveraging the Gland-Cenexi customer base to unlock new business in Europe.

References

  1. Annual Report May 2025
  2. Investor Presentation Nov 2025
  3. Result Jan 2026

Gland Pharma FAQ

Gland Pharma today is trading in the green, up by 0.7% at ₹3,095.9.
Gland Pharma is currently trading up 0.7% on an intraday basis. In the past week the stock rose 9.52%. Stock has been up 23.69% in the past quarter and rose 60.5% in the past year. You can view this in the share price history/seasonality section.
Gland Pharma is listed on NSE with the ticker GLAND and on BSE as 543245. It's currently trading on NSE at a share price of ₹3,095.9 and on BSE with a share price of ₹3,100.
The market cap of Gland Pharma is ₹51,085.72 Cr. as of Oct 30, 2026.
Gland Pharma announced a FINAL dividend of 2000% which equals ₹20 in Aug 11, 2026.The last two ex-dates for Gland Pharma were Aug 14, 2025 and Aug 16, 2024. To view the full dividend history of Gland Pharma click here.
Gland Pharma has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Gland Pharma reported ₹1,861.5 Cr. in revenue, ₹316.96 Cr. in net profit, and ₹550.6 Cr. in EBITD as of Aug 10, 2026 for Q1 FY26-27.
According to the predictions of 14 analysts, the share price prediction for Gland Pharma is ₹2,964.36 with a downside of 4%.
The PE ratio of Gland Pharma is 45.26 as of Oct 30, 2026.
The PB ratio of Gland Pharma is 4.79 as of Oct 30, 2026.
You can view the latest analyst reports on the Gland Pharma reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×